See the DrugPatentWatch profile for Odactra
What exclusivity protections does Odactra have (and how long do they last)?
Odactra is an allergen immunotherapy tablet. “Exclusivity” for a medicine is usually driven by regulatory data protection and patent rights, which can differ by country and by the specific molecule/product and indication.
From the information provided here, there are no details on Odactra’s specific exclusivity start/end dates, patent numbers, or whether the protection is from patents, biologics-style exclusivity, data exclusivity, or marketing authorization exclusivity.
How do patent expiry and regulatory data exclusivity interact for drugs like Odactra?
In general, generic or competing products can be constrained by two different mechanisms:
- Patents can block manufacture/sale of the product (or specific claims) until their expiration.
- Regulatory exclusivity (such as data exclusivity or marketing exclusivity) can block reliance on the originator’s clinical data and can delay approval of alternatives even after some patent coverage ends.
Which one is the binding constraint for Odactra depends on what is patented (and in which jurisdictions) and what kind of exclusivity was granted for the marketing authorization.
Can competitors launch before Odactra’s exclusivity ends?
It can happen in some cases, depending on local rules:
- A competitor may launch a product that does not infringe relevant patents (if it can).
- Regulators may still approve other products after exclusivity ends, even if some patent issues remain.
- Litigation can delay entry if a patent is asserted and courts issue injunctions.
The exact answer for Odactra needs the specific patent/exclusivity timeline and the country (e.g., US vs EU vs UK).
What do people usually mean by “Odactra exclusivity” when they search?
Searchers commonly mean one of these:
- “When does Odactra lose exclusivity in the US/EU?”
- “When does the last patent expire?”
- “When does regulatory data exclusivity end (so generics can file/launch)?”
If you tell me the country (US, EU, UK, etc.) and whether you mean patents vs regulatory exclusivity, I can narrow down the likely governing protections and what date matters.
What I need from you to give a precise exclusivity date
Share any of the following and I’ll tailor the answer:
- The country or regulator (FDA, EMA, UK MHRA, etc.)
- The indication wording you mean by Odactra (commonly house dust mite allergic rhinitis is the core context)
- Whether you want the “last patent expiry” date or “regulatory exclusivity” end date
Sources
No sources were provided with your question, so I can’t cite Odactra’s exclusivity details.